Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Harmony Biosciences Holdings (HRMY) Retained Earnings (2019 - 2025)

Harmony Biosciences Holdings' Retained Earnings history spans 7 years, with the latest figure at $160.9 million for Q4 2025.

  • For Q4 2025, Retained Earnings rose 7160.97% year-over-year to $160.9 million; the TTM value through Dec 2025 reached $160.9 million, up 7160.97%, while the annual FY2025 figure was $160.9 million, 7160.97% up from the prior year.
  • Retained Earnings for Q4 2025 was $160.9 million at Harmony Biosciences Holdings, up from $357000.0 in the prior quarter.
  • Across five years, Retained Earnings topped out at $160.9 million in Q4 2025 and bottomed at -$480.8 million in Q1 2021.
  • The 5-year median for Retained Earnings is -$52.7 million (2023), against an average of -$149.1 million.
  • The largest annual shift saw Retained Earnings crashed 718331.03% in 2023 before it surged 37515.38% in 2025.
  • A 5-year view of Retained Earnings shows it stood at -$453.6 million in 2021, then skyrocketed by 40.01% to -$272.1 million in 2022, then soared by 47.35% to -$143.3 million in 2023, then skyrocketed by 101.55% to $2.2 million in 2024, then surged by 7160.97% to $160.9 million in 2025.
  • Per Business Quant, the three most recent readings for HRMY's Retained Earnings are $160.9 million (Q4 2025), $357000.0 (Q3 2025), and $87.6 million (Q2 2025).